Home
AudioAsylum Trader
Inmate Central

Inmate Central, where civil and family-friendly discourse about off-audio topics (other than religion and politics) is welcome.

For Sale Ads

FAQ / News / Events

 

Use this form to submit comments directly to the Asylum moderators for this forum. We're particularly interested in truly outstanding posts that might be added to our FAQs.

You may also use this form to provide feedback or to call attention to messages that may be in violation of our content rules.

You must login to use this feature.

Inmate Login


Login to access features only available to registered Asylum Inmates.
    By default, logging in will set a session cookie that disappears when you close your browser. Clicking on the 'Remember my Moniker & Password' below will cause a permanent 'Login Cookie' to be set.

Moniker/Username:

The Name that you picked or by default, your email.
Forgot Moniker?

 
 

Examples "Rapper", "Bob W", "joe@aol.com".

Password:    

Forgot Password?

 Remember my Moniker & Password ( What's this?)

If you don't have an Asylum Account, you can create one by clicking Here.

Our privacy policy can be reviewed by clicking Here.

Inmate Comments

From:  
Your Email:  
Subject:  

Message Comments

   

Original Message

anecdotal evidence isn't useless-- but it is "n = 1"

Posted by mhardy6647 on April 18, 2017 at 16:09:36:

-- and must be considered in light of that.

In my early "pro" days, I worked for a biotech company with an interesting anticancer immunotoxin "platform". Their original Phase 1 studies (which are used to assess the safety of a new drug, and not its efficacy) were conducted not in healthy volunteers but in (relapsed) cancer patients who had failed conventional therapies for their specific cancer.

Several of these very sick patients exhibited partial remissions after treatment with the drug, and there was at least one total remission.

The drug later failed to demonstrate efficacy in a standard Phase 2/3 protocol (cancer studies, at least in those days, were typically NOT placebo controlled, for rather obvious ethical reasons).

The PR and CR results in Phase 1 were anecdotal :-) The study wasn't designed to demonstrate, much less quantify, efficacy, and the drug was later shown NOT to be efficacious in an appropriately "powered" study.

BUT, for the folks who exhibited CR or PR, it WAS indeed efficacious.

Anecdotal evidence.
Not "false evidence" -- just difficult to interpret.

The company in question later developed a different platform for immunotoxins and subsequently did develop effective cancer drugs.